Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Epidemiology, Clinical Research, Genomics, Chronic Myeloid Malignancies, CMML, Diseases, Myeloid Malignancies, Biological Processes
Somatic mutations in TET2 are present in ~60% of chronic myelomonocytic leukemia (CMML) patients and are associated with improved median overall (mOS) and acute leukemia free survival (mLFS). Multiple TET2 mutations are detected in ~50% of such cases and are thought to confer additional benefit. Whether these benefits apply to the molecularly distinct myelodysplastic (MD) and myeloproliferative (MP) CMML subtypes is unknown. This study assesses the impact of the number and type of TET2 mutations across the MD and MP-CMML subtypes.
Methods
CMML patients seen at Mayo Clinic (n = 400, 47%) and MD Anderson Cancer Center (n = 449, 53%) were included with IRB approval. Analyses considered the clinical and molecular data at diagnosis or first referral. Truncating (frameshift or nonsense) mutations in TET2 were further annotated by location in either the proximal genome targeting domain (aa 1 – 1128) or distal catalytic domain (aa 1129 – 1936) as described (Coltro, 2020). Categorical variables were compared by Pearson Chi squared and continuous by Mann-Whitney U or Kruskal-Wallis tests. Univariate and multivariate analyses utilized Cox proportional hazards models with continuous variables binarized by receiver operator curves. Kaplan-Meier analyses were censored at hematopoietic cell transplantation (HCT). P < 0.05 was considered significant. Calculations used BlueSky (v10.3.1) or Prism (v10.2.3).
Results
In a cohort of 849 CMML patients (median age 71 years, 32% female, 90% white), 454 (54%) were classified as MD-CMML and 394 (46%) as MP-CMML. Cumulatively, 664 somatic TET2 mutations were identified across the MD (n = 415, 63%) and MP-CMML (n = 249, 38%) subgroups, with ≥1 TET2 mutation in 57% vs 44% (p < 0.001) and ≥2 TET2mutations in 33% vs 20% (p = 0.001) , respectively. The median (range) number of TET2 mutations in MD vs MP-CMML was 1 (0 – 4) vs 0 (0 – 3; p < 0.001). Truncating frameshift or nonsense mutations comprised 86% vs 78% of mutations in each group with hypomorphic missense mutations comprising 13% vs 20% (p = 0.03). Proximal (48% vs 43%) and distal (38% vs 35%) truncations were evenly distributed between MD and MP-CMML (p = 0.91).
In both the MD and MP subgroups as well as the overall cohort (p < 0.01 each), increasing number of TET2 mutations (0 vs 1 vs ≥2) was associated with higher median hemoglobin (10.3 vs 11.4 vs 12.0 g/dL), fewer mean peripheral blasts (1.3% vs 0.5% vs 0.3%), and a higher proportion of normal karyotypes (60% vs 76% vs 79%). Likewise, co-mutations were increasingly frequent in SRSF2 (36% vs 45% vs 53%) and less frequent in IDH2 (9% vs 1% vs 1%) and SETBP1 (14% vs 4% vs 0%) throughout the cohort. TET2 mutations were mutually exclusive with ETV6, GATA2, IDH1, and WT1 mutations.
Uniquely, MD-CMML cases with TET2 mutations (0 vs 1 vs ≥2) were enriched for co-mutations in ZRSR2 (5% vs 13% vs 9%) and had fewer co-mutations in both ASXL1 (47% vs 34% vs 28%) and U2AF1 (11% vs 6% vs 3%). In MP-CMML, co-mutations in CBL (11% vs 20% vs 27%) were increased while co-mutations in BCOR (6% vs 1% vs 0%) were decreased. Accordingly, the favorable ASXL1WT/TET2MT genotype was more common in MD (39% vs 22%), while the adverse ASXL1MT/TET2WT genotype was more common in MP-CMML (20% vs 33%; p < 0.001).
In multivariate analyses, the presence of ≥2 TET2 mutations was favorably associated with OS and LFS in both MD and MP-CMML (hazard ratios 0.53 – 0.67, p < 0.04) independent of several clinical and genetic features including ASXL1 mutations and abnormal karyotype. Beyond the number of TET2 mutations, however, neither the mutation class (truncating vs hypomorphic) nor location (proximal vs distal) further affected OS or LFS. Likewise, although the median variant allele fraction (VAF) was lower in MD vs MP-CMML (42% vs 46%, p < 0.001), VAF did not impact survival. Accordingly, the mOS for patients with 0, 1, or ≥2 TET2 mutations was 29, 58, and 75 months in MD-CMML and 19, 26, and 39 months in MP-CMML, respectively (p < 0.001 each). The mLFS was similarly improved to 26, 52, and 67 months in MD-CMML (p < 0.001) and 16, 22, and 31 months in MP-CMML (p = 0.003).
CONCLUSIONS
This multicenter study demonstrates that the favorable impact of multiple TET2 mutations in CMML extends to both the MD and MP subtypes. In MD-CMML, multiple TET2 mutations segregate against adverse ASXL1 mutations while, in MP-CMML, they appear to offset the impact of adverse RAS pathway mutations. Thus, multiple TET2 mutations may identify a lower-risk subgroup of MP-CMML patients.
Disclosures: Loghavi: Pathology Education Partners; VJ HemeOnc, College of American Pathologists, OncLive, ICCS, MD Education, NCCN, MashUp Media, NCTN, Aptitude Health: Honoraria; Guidepoint; QualWorld; Gerson Lehrman Group, AlphaSight, Arima, Qiagen, Opinion Health: Consultancy; Astellas, Amgen: Research Funding; Abbvie: Current holder of stock options in a privately-held company; Syndx, Servier, BMS: Membership on an entity's Board of Directors or advisory committees; Abbvie, Daiichi Sankyo, BluePrint Medicine, Caris Diagnostics, Recordati, Servier: Consultancy. Chien: Rigel Pharmaceuticals: Consultancy; AbbVie: Consultancy. Gangat: DISC Medicine: Consultancy, Other: Advisory Board ; Agios: Other: Advisory Board. Mangaonkar: BMS: Research Funding; Incyte: Research Funding; Novartis: Research Funding. Garcia-Manero: Aprea: Research Funding; Genentech: Other: Personal fees; Helsinn: Other: Personal fees; Astex: Other: Personal fees; Forty Seven: Research Funding; Genentech: Research Funding; Merck: Research Funding; Amphivena: Research Funding; Astex: Research Funding; H3 Biomedicine: Research Funding; Novartis: Research Funding; Janssen: Research Funding; Curis: Research Funding; Bristol Myers Squibb: Other: Personal fees, Research Funding; AbbVie: Research Funding; Helsinn: Research Funding; Onconova: Research Funding. Montalban-Bravo: Takeda: Research Funding; Rigel: Research Funding. Patnaik: Polaris: Research Funding; Kura Oncology: Research Funding; Epigenetix: Research Funding; Solu therapeutics: Research Funding; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees; StemLine: Research Funding.
See more of: Oral and Poster Abstracts